Recent advances in drug eluting stents
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
One of the most common medical interventions to reopen an occluded vessel is the implantation of a coronary stent. While this method of treatment is effective initially, restenosis, or the re-narrowing of the artery frequently occurs largely due to neointimal hyperplasia of smooth muscle cells. Drug eluting stents were developed in order to provide local, site-specific, controlled release of drugs that can inhibit neointima formation. By implementing a controlled release delivery system it may be possible to control the time release of the pharmacological factors and thus be able to bypass some of the critical events associated with stent hyperplasia and prevent the need for subsequent intervention. However, since the advent of first-generation drug eluting stents, long-term adverse effects have raised concerns regarding their safety. These limitations in safety and efficacy have triggered considerable research in developing biodegradable stents and more potent drug delivery systems. In this review, we shed light on the current state-of-the-art in drug eluting stents, problems related to them and highlight some of the ongoing research in this area.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600 · cited 1×
“This Pacific Yew tree bark extract has been substantiated to wield its anti-proliferative abilities in order to minimize in-stent restenosis (Wani et al., 1971; Schiff et al., 1979).”
BackgroundGuha, M., & Mackman, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203298200 · Cited by 799 · cited 1×
“Inhibition of mTOR by the sirolimus-FKBP12 complex in endothelial cells, thus, leads to thrombin and tumor necrosis factor-α prompted increased tissue factor expression and activity (Guha and Mackman, 2002).”
BackgroundTissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications
Steffel, J., Lüscher, T. F., & Tanner, F. C. (2006) · Circulation · doi:10.1161/circulationaha.105.567297 · Cited by 456
The Road to Bioabsorbable Stents: Reaching Clinical Reality?
Erne, P., Schier, M., & Resink, T. J. (2006) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-004-0341-9 · Cited by 249
Cited by
Smart drug delivery systems: from fundamentals to the clinic
Alvarez-Lorenzo, C., & Concheiro, A. (2014) · Chem. Commun. · doi:10.1039/c4cc01429d · Cited by 415
Targeting mTOR to reduce Alzheimer-related cognitive decline: from current hits to future therapies.
Tramutola, A., Lanzillotta, C., & Di Domenico, F. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1244482 · Cited by 69
“compared to rapamycin, was designed to have a shorter in vivo half-life [60].”
Background
Metadata
- Authors
- Puranik, A. S., Dawson, E. R., & Peppas, N. A.
- Venue
- International Journal of Pharmaceutics
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 441
- Issue
- 1-2
- Pages
- 665-679
- ISSN
- 0378-5173 (ISSN-L)
- OpenAlex
- W1987715200
- Cited by
- 176
- References
- 4
- FWCI
- 10.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent advances in drug eluting stents. https://app.cochat.ai/papers/10.1016/j.ijpharm.2012.10.029
- The paper
- Puranik, A. S., Dawson, E. R., & Peppas, N. A. (2013). Recent advances in drug eluting stents. International Journal of Pharmaceutics. https://doi.org/10.1016/j.ijpharm.2012.10.029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.